Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2009138707) QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   
Pub. No.: WO/2009/138707 International Application No.: PCT/GB2008/001647
Publication Date: 19.11.2009 International Filing Date: 13.05.2008
IPC:
C07D 453/02 (2006.01) ,A61K 31/439 (2006.01) ,A61P 11/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
453
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
02
containing not further condensed quinuclidine ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
439
the ring forming part of a bridged ring system, e.g. quinuclidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
Applicants:
FORD, Rhonan, Lee [GB/GB]; GB (UsOnly)
MATHER, Andrew, Nigel [GB/GB]; GB (UsOnly)
METE, Antonio [IT/GB]; GB (UsOnly)
BULL, Richard, James [GB/GB]; GB (UsOnly)
SKIDMORE, Elizabeth, Anne [GB/GB]; GB (UsOnly)
ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje, SE (AllExceptUS)
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED [GB/GB]; Fulmer Hall Windmill Road Fulmer Slough SL3 6HD, GB (AllExceptUS)
Inventors:
FORD, Rhonan, Lee; GB
MATHER, Andrew, Nigel; GB
METE, Antonio; GB
BULL, Richard, James; GB
SKIDMORE, Elizabeth, Anne; GB
Agent:
STANSFIELD, Kevin; AstraZeneca AB Global Intellectual Property SE-151 85 Södertälje, SE
Priority Data:
Title (EN) QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
(FR) DÉRIVÉS DE QUINUCLIDINE UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES M3
Abstract:
(EN) The invention provides named compounds of formula (I), wherein R4 is a N- sustituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for' the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
(FR) L'invention porte sur des composés représentés par la formule (I), dans laquelle R4 est une quinuclidine substituée en N (I), sur des compositions pharmaceutiques les contenant et sur un procédé de fabrication de ces compositions pharmaceutiques. L'invention porte également sur leur utilisation en thérapie pour le traitement d'affections à médiation par les récepteurs muscariniques M3, telles qu'une bronchopneumopathie chronique obstructive.
 front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)